As Teva Pharmaceutical (TEVA) Market Value Declined, Holder Northern Cross Has Decreased Its Position by $10.25 Million; As Kkr & Co LP Del (KKR) Market Valuation Declined, Holder Concourse Capital Management Has Cut Stake by $677,061

April 17, 2018 - By Hazel Jackson

KKR & Co. L.P. (NYSE:KKR) Logo

Concourse Capital Management Llc decreased its stake in Kkr & Co LP Del (KKR) by 7.39% based on its latest 2017Q4 regulatory filing with the SEC. Concourse Capital Management Llc sold 32,241 shares as the company’s stock declined 3.82% with the market. The hedge fund held 404,208 shares of the investment managers company at the end of 2017Q4, valued at $8.51 million, down from 436,449 at the end of the previous reported quarter. Concourse Capital Management Llc who had been investing in Kkr & Co LP Del for a number of months, seems to be less bullish one the $17.19B market cap company. The stock increased 0.82% or $0.17 during the last trading session, reaching $20.89. About 1.05 million shares traded. KKR & Co. L.P. (NYSE:KKR) has risen 15.21% since April 17, 2017 and is uptrending. It has outperformed by 3.66% the S&P500.

Northern Cross Llc decreased its stake in Teva Pharmaceutical (TEVA) by 2.5% based on its latest 2017Q4 regulatory filing with the SEC. Northern Cross Llc sold 569,597 shares as the company’s stock declined 11.04% with the market. The institutional investor held 22.19 million shares of the major pharmaceuticals company at the end of 2017Q4, valued at $420.59M, down from 22.76 million at the end of the previous reported quarter. Northern Cross Llc who had been investing in Teva Pharmaceutical for a number of months, seems to be less bullish one the $18.08 billion market cap company. The stock decreased 1.53% or $0.2758 during the last trading session, reaching $17.7842. About 4.66M shares traded. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has declined 49.50% since April 17, 2017 and is downtrending. It has underperformed by 61.05% the S&P500.

Analysts await Teva Pharmaceutical Industries Limited (NYSE:TEVA) to report earnings on May, 10. They expect $0.62 earnings per share, down 39.81% or $0.41 from last year’s $1.03 per share. TEVA’s profit will be $630.45 million for 7.17 P/E if the $0.62 EPS becomes a reality. After $0.91 actual earnings per share reported by Teva Pharmaceutical Industries Limited for the previous quarter, Wall Street now forecasts -31.87% negative EPS growth.

Among 35 analysts covering Teva Pharma (NYSE:TEVA), 9 have Buy rating, 8 Sell and 18 Hold. Therefore 26% are positive. Teva Pharma had 149 analyst reports since July 21, 2015 according to SRatingsIntel. Piper Jaffray maintained Teva Pharmaceutical Industries Limited (NYSE:TEVA) rating on Thursday, August 3. Piper Jaffray has “Hold” rating and $2300 target. Credit Suisse downgraded the shares of TEVA in report on Friday, August 4 to “Neutral” rating. Oppenheimer reinitiated the stock with “Outperform” rating in Wednesday, December 7 report. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) has “Buy” rating given on Tuesday, May 10 by Mizuho. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) has “Hold” rating given on Thursday, February 1 by BTIG Research. On Friday, February 9 the stock rating was downgraded by PiperJaffray to “Underweight”. RBC Capital Markets maintained Teva Pharmaceutical Industries Limited (NYSE:TEVA) on Sunday, March 25 with “Hold” rating. The stock has “Hold” rating by Guggenheim on Wednesday, January 31. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) earned “Hold” rating by Cowen & Co on Wednesday, October 4. The company was downgraded on Monday, August 7 by Morgan Stanley.

Investors sentiment increased to 1.07 in Q4 2017. Its up 0.10, from 0.97 in 2017Q3. It increased, as 29 investors sold KKR shares while 84 reduced holdings. 38 funds opened positions while 83 raised stakes. 308.46 million shares or 7.55% more from 286.80 million shares in 2017Q3 were reported. Mckinley Management Lc Delaware invested in 0.11% or 101,242 shares. Illinois-based First Midwest Savings Bank Trust Division has invested 0.18% in KKR & Co. L.P. (NYSE:KKR). Citigroup holds 0.16% or 9.63 million shares. Wells Fargo & Mn holds 3.56M shares. 576,003 are held by Blackrock Incorporated. Bridgecreek Investment Mgmt Limited Liability Company has invested 0.57% in KKR & Co. L.P. (NYSE:KKR). Blair William Co Il has invested 0% in KKR & Co. L.P. (NYSE:KKR). Private Advisor Grp Inc Lc owns 31,348 shares. Kistler holds 0.02% or 2,318 shares in its portfolio. Putnam Investments Limited Liability Company has invested 0.36% in KKR & Co. L.P. (NYSE:KKR). 154,973 were accumulated by Benchmark Capital Advisors. Moreover, First Pacific Ltd Liability Corp has 0.01% invested in KKR & Co. L.P. (NYSE:KKR). Illinois-based Northern Tru has invested 0% in KKR & Co. L.P. (NYSE:KKR). Covey Cap Advsr Ltd holds 203,503 shares. Moody Bancshares Trust Division owns 31,225 shares or 0.03% of their US portfolio.

Since February 9, 2018, it had 1 insider buy, and 0 sales for $10.52 million activity.

Analysts await KKR & Co. L.P. (NYSE:KKR) to report earnings on April, 26. They expect $0.18 EPS, down 72.31% or $0.47 from last year’s $0.65 per share. KKR’s profit will be $148.10M for 29.01 P/E if the $0.18 EPS becomes a reality. After $0.48 actual EPS reported by KKR & Co. L.P. for the previous quarter, Wall Street now forecasts -62.50% negative EPS growth.

KKR & Co. L.P. (NYSE:KKR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.